Médico especialista en Endocrinología.
Instituto Nacional de Ciencias Médicas y Nutrición.
Especialista en Cardiología.
Hospital de Cardiología, Centro Médico Nacional Siglo XXI.
Cédula 4011182.
Stone MA, et al. Quality of care of people with type 2 diabetes in eight European countries: findings from the Guideline Adherence to Enhance Care (GUIDANCE) study. Diabetes Care. 2013 Sep;36(9):2628-38.
de Pablos-Velasco P, et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin Endocrinol (Oxf). 2014 Jan;80(1):47-56.
Nam S, et al. Barriers to diabetes management: patient and provider factors. Diabetes Res Clin Pract. 2011 Jul;93(1):1-9.
Dezii DM, et al. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J. 2002 Jan;95(1):68-71.
Dailey G, et al. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin Ther. 2001 Aug;23(8):1311-20.
Rajagopalan R, et al. Medication compliance in type 2 diabetes patients: retrospective data analysis. Value Health 2003;6:328.
Lawrence DB, et al. Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program. J Manag Care Pharm. 2006 Jul-Aug;12(6):466-71.
Rozenfeld Y, et al. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care. 2008 Feb;14(2):71-5.
Vilsbøll T, et al. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia. 2002 Aug;45(8):1111-9.
Wajchenberg BL. beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007 Apr;28(2):187-218.
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007 May;132(6):2131-57.
Reach G, et al. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 2017 Dec;43(6):501-511.
Khunti K, Millar-Jones D. Clinical inertia to insulin initiation and intensification in the UK: A focused literature review. Prim Care Diabetes. 2017 Feb;11(1):3-12.
Boye K, et al. Patients' preferences for once-daily oral versus once-weekly injectable diabetes medications: The REVISE study. Diabetes Obes Metab. 2021 Feb;23(2):508-519.
Fallowfield L, et al. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol. 2006 Feb;17(2):205-10.
García Pérez LE, et al. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013 Dec;4(2):175-94.
Anderson SL, et al. Oral semaglutide in type 2 diabetes. J Diabetes Complications. 2020 Apr;34(4):107520.